These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 19739077

  • 1. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
    Pilzer D, Saar M, Koya K, Fishelson Z.
    Int J Cancer; 2010 Mar 15; 126(6):1428-35. PubMed ID: 19739077
    [Abstract] [Full Text] [Related]

  • 2. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis.
    Pilzer D, Fishelson Z.
    Int Immunol; 2005 Sep 15; 17(9):1239-48. PubMed ID: 16091382
    [Abstract] [Full Text] [Related]

  • 3. Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity.
    Saar Ray M, Moskovich O, Iosefson O, Fishelson Z.
    J Biol Chem; 2014 May 23; 289(21):15014-22. PubMed ID: 24719326
    [Abstract] [Full Text] [Related]

  • 4. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9.
    Rozenberg P, Ziporen L, Gancz D, Saar-Ray M, Fishelson Z.
    Cell Death Dis; 2018 Feb 02; 9(2):150. PubMed ID: 29396434
    [Abstract] [Full Text] [Related]

  • 5. Mortalin sensitizes human cancer cells to MKT-077-induced senescence.
    Deocaris CC, Widodo N, Shrestha BG, Kaur K, Ohtaka M, Yamasaki K, Kaul SC, Wadhwa R.
    Cancer Lett; 2007 Jul 18; 252(2):259-69. PubMed ID: 17306926
    [Abstract] [Full Text] [Related]

  • 6. Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis.
    Reiter Y, Ciobotariu A, Jones J, Morgan BP, Fishelson Z.
    J Immunol; 1995 Aug 15; 155(4):2203-10. PubMed ID: 7636268
    [Abstract] [Full Text] [Related]

  • 7. Regulation of Complement-Dependent Cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217.
    Hillman Y, Mazkereth N, Farberov L, Shomron N, Fishelson Z.
    J Immunol; 2016 Jun 15; 196(12):5156-65. PubMed ID: 27183614
    [Abstract] [Full Text] [Related]

  • 8. Rhodacyanine dye MKT-077 inhibits in vitro telomerase assay but has no detectable effects on telomerase activity in vivo.
    Wadhwa R, Colgin L, Yaguchi T, Taira K, Reddel RR, Kaul SC.
    Cancer Res; 2002 Aug 01; 62(15):4434-8. PubMed ID: 12154051
    [Abstract] [Full Text] [Related]

  • 9. Complement triggers relocation of Mortalin/GRP75 from mitochondria to the plasma membrane.
    Mazkereth N, Rocca F, Schubert JR, Geisler C, Hillman Y, Egner A, Fishelson Z.
    Immunobiology; 2016 Dec 01; 221(12):1395-1406. PubMed ID: 27475989
    [Abstract] [Full Text] [Related]

  • 10. SMR peptide antagonizes mortalin promoted release of extracellular vesicles and affects mortalin protection from complement-dependent cytotoxicity in breast cancer cells and leukemia cells.
    Huang MB, Wu JY, Lillard J, Bond VC.
    Oncotarget; 2019 Sep 10; 10(52):5419-5438. PubMed ID: 31534628
    [Abstract] [Full Text] [Related]

  • 11. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement.
    Reiter Y, Ciobotariu A, Fishelson Z.
    Eur J Immunol; 1992 May 10; 22(5):1207-13. PubMed ID: 1577063
    [Abstract] [Full Text] [Related]

  • 12. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function.
    Wadhwa R, Sugihara T, Yoshida A, Nomura H, Reddel RR, Simpson R, Maruta H, Kaul SC.
    Cancer Res; 2000 Dec 15; 60(24):6818-21. PubMed ID: 11156371
    [Abstract] [Full Text] [Related]

  • 13. Mortalin-based cytoplasmic sequestration of p53 in a nonmammalian cancer model.
    Walker C, Böttger S, Low B.
    Am J Pathol; 2006 May 15; 168(5):1526-30. PubMed ID: 16651619
    [Abstract] [Full Text] [Related]

  • 14. Mortalin inhibition in experimental Parkinson's disease.
    Chiasserini D, Tozzi A, de Iure A, Tantucci M, Susta F, Orvietani PL, Koya K, Binaglia L, Calabresi P.
    Mov Disord; 2011 Aug 01; 26(9):1639-47. PubMed ID: 21542017
    [Abstract] [Full Text] [Related]

  • 15. Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines.
    Gestl EE, Anne Böttger S.
    Biochem Biophys Res Commun; 2012 Jun 29; 423(2):411-6. PubMed ID: 22683628
    [Abstract] [Full Text] [Related]

  • 16. Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence.
    Grover A, Priyandoko D, Gao R, Shandilya A, Widodo N, Bisaria VS, Kaul SC, Wadhwa R, Sundar D.
    Int J Biochem Cell Biol; 2012 Mar 29; 44(3):496-504. PubMed ID: 22155302
    [Abstract] [Full Text] [Related]

  • 17. Relevance of mortalin to cancer cell stemness and cancer therapy.
    Yun CO, Bhargava P, Na Y, Lee JS, Ryu J, Kaul SC, Wadhwa R.
    Sci Rep; 2017 Feb 06; 7():42016. PubMed ID: 28165047
    [Abstract] [Full Text] [Related]

  • 18. Emission of membrane vesicles: roles in complement resistance, immunity and cancer.
    Pilzer D, Gasser O, Moskovich O, Schifferli JA, Fishelson Z.
    Springer Semin Immunopathol; 2005 Nov 06; 27(3):375-87. PubMed ID: 16189651
    [Abstract] [Full Text] [Related]

  • 19. Mortalin peptides exert antitumor activities and act as adjuvants to antibody-mediated complement-dependent cytotoxicity.
    Jubran R, Saar-Ray M, Wawruszak A, Ziporen L, Donin N, Bairey O, Fishelson Z.
    Int J Oncol; 2020 Oct 06; 57(4):1013-1026. PubMed ID: 32700755
    [Abstract] [Full Text] [Related]

  • 20. Analogs of the Heat Shock Protein 70 Inhibitor MKT-077 Suppress Medullary Thyroid Carcinoma Cells.
    Hong SK, Starenki D, Johnson OT, Gestwicki JE, Park JI.
    Int J Mol Sci; 2022 Jan 19; 23(3):. PubMed ID: 35162987
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.